From AAD 2026 to Practice: Highlighting Key Clinical Advances

Summer may be approaching, but Dermatology Times is still reminiscing about the endless data shared at the 2026 American Academy of Dermatology (AAD) Annual Meeting. Held in Denver, Colorado, from March 27 to 31, the meeting brought together clinicians from around the globe to share pipeline updates, research advancements, and—one of the major draws—late-breaking data.

This year’s meeting did not disappoint, offering highly anticipated late-breaker presentations. Dermatology Times’ Editor in Chief Christopher G. Bunick, MD, PhD, recapped many of the data readouts in this month’s Letter From the Editor in Chief.

In atopic dermatitis, his highlights included next-generation IL-4 receptor α inhibitors (rademikibart, MG-K10), OX40-OX40L modulation (amlitelimab), and STAT6 degradation (KT-621), which showed strong skin clearance and early activity. Pediatric data supported nemolizumab and topical roflumilast. Abrocitinib benefited chronic hand eczema, whereas rezpegaldesleukin offered a novel mechanism in alopecia areata. In psoriasis, icotrokinra, zasocitinib, and envudeucitinib approached biologic-level efficacy, with ixekizumab plus tirzepatide suggesting cardiometabolic benefit. Further advances in vitiligo (upadacitinib), hidradenitis suppurativa (povorcitinib, sonelokimab), and dermatomyositis (brepocitinib) reflect a broader shift toward targeted, systemically integrated dermatologic care.

This month’s cover spread continues to dive into AAD data, with in-depth looks at amlitelimab, icotrokinra, zasocitinib, envudeucitinib, ixekizumab, bimekizumab, sonelokimab, and izokibep.

MORE ON DRUGS TO WATCH

Also featured in our May issue is Joe Gatti, DMSc, MPAS, MBA, PA-C, on the most important practice document that clinicians may not take seriously enough; Kathleen Moe, MD, on why clinicians should open their own practice and the logistics associated with it; and Arash Izadpanah, MD, and Scott Hamilton, MBA, COT, on the importance of medical mission trips that provide practical tools that look beyond “voluntourism.”

As always, Dermatology Times delivers the most up-to-date clinical content, featuring innovative studies, FDA approvals, exclusive interviews, and expert perspectives. Stay informed with the latest data by subscribing to Dermatology Times’ e-newsletters and following us on LinkedIn, Instagram, Facebook, X, and YouTube.

MORE FROM OUR PRINT PUBLICATION